Science Corporation, a brain-computer interface startup founded by former Neuralink president Max Hodak, has announced a new division focused on extending the viability of human organs for transplantation. The company unveiled a prototype machine designed to preserve organs for longer periods. This initiative expands beyond their core work in neural technology.
Founded in 2021, Science Corporation initially gained attention for its advancements in brain-computer interfaces under the leadership of Max Hodak, who served as Neuralink's first president. Now, the company is venturing into biotechnology with a dedicated division aimed at prolonging the life of human organs outside the body.
The new effort centers on a prototype machine that seeks to maintain organ viability for extended durations, potentially improving outcomes in organ transplants. This development addresses a critical challenge in medical logistics, where time-sensitive preservation is essential.
Hodak's background in neurotechnology underscores the innovative approach, though the focus here shifts to broader health applications. As organ shortages persist globally, such technologies could enhance donation programs and reduce waste from preservation failures.
Science Corporation emphasizes that this division complements their existing work, without specifying immediate rollout plans or clinical trials. The announcement highlights the intersection of biotech and AI-driven solutions in healthcare.
